13.9C
Delhi
Monday, January 18, 2021

Aurobindo Pharma & Covaxx to develop corona vaccine for India, Unicef

- Advertisement -

Covid-19 vaccine could come within 1 year: WHO chiefNew Delhi, Dec 24 (IANS) Aurobindo Pharma Limited and Covaxx, a US-based company, have entered into an Exclusive License Agreement to produce, market and manufacture UB-612 for India and the UN Children’s Fund (Unicef) agency, the first Multitope Peptide-based vaccine to combat Covid-19.

For the vaccine product, COVAXX is currently performing a Phase 1 clinical trial.

Commenting on the extension, N. “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.”We are proud to partner with COVAXX to create the first ever synthetic peptide-based vaccine to combat the pandemic of Covid-19. This vaccine has immense potential to prevent the spread of the pandemic from shedding and thereby containing.

READ ALSO:  Assocham recommends graded opening of economy

Under the signed agreement, Aurobindo Pharma acquired exclusive rights in India and Unicef to develop, produce and distribute the Covaxx UB-612 vaccine, as well as non-exclusive rights in other select emerging and developed markets.

The completed doses of UB-612 will be manufactured by Aurobindo at its Hyderabad plant.

Aurobindo has a multi-dose presentation capacity of 220 million (22 crore) doses and is constructing additional facilities with a total capacity of approximately 480 million (48 crore) doses by June 2021.

READ ALSO:  Awaiting govt proposal, farmer leaders hold informal discussions at Singhu

“Covaxx is committed to providing an equitable distribution of UB-612 by prioritizing emerging markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX.

We need to create partners with the strongest capabilities, such as Aurobindo, during this global health crisis response, to prioritize the production and delivery of our vaccine. As one of the leading industry players with a strong track record of vaccine implementation and investment, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to help our vaccine execution and investment.

READ ALSO:  India's active COVID-19 cases drop below 5-lakh mark for first time after 106 days

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Parliamentary panel summons FB, Twitter officials on Jan 21

New Delhi, Jan 17 (IANS) The Parliamentary Committee on Information Technology has issued summons to officials of Facebook and Twitter for January 21, to...

447 adverse events across India post-vaccination, 3 serious

New Delhi, Jan 17 (IANS) A total of 447 Adverse Events Following Immunisation (AEFI) have been reported in the last two days of the...

New-age insurance, green energy stocks in queue for Nifty50 entry

Mumbai, Jan 17 (IANS) New-age stocks from insurance, green energy and internet space are in the queue to enter benchmark Nifty50 index, which reflects...

Centre-farmers’ standoff will resolve through dialogues: Vice Prez

New Delhi, Jan 17 (IANS) Vice President M. Venkaiah Naidu on Sunday said that the current standoff between the protesting farmers and the Centre...